NuCana Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

NuCana hat ein Gesamteigenkapital von £3.8M und eine Gesamtverschuldung von £0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen £20.1M bzw. £16.3M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

UK£0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	UK£11.64m
Eigenkapital	UK£3.80m
Gesamtverbindlichkeiten	UK£16.27m
Gesamtvermögen	UK£20.07m

Jüngste Berichte zur Finanzlage

Recent updates

Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

Aug 21

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Mar 14

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

Oct 15

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

Jul 01

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Mar 15

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Nov 30

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 22

NuCana GAAP EPS of -£0.07

Aug 17

NuCana regains Nasdaq compliance

Jul 27

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Jul 13

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

May 02

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

Jan 17

NuCana: Preparing For A Critical 2022

Dec 08

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

Sep 30

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

Sep 11

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Jun 01

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

Feb 15

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Dec 22

NuCana (NCNA) Investor Presentation - Slideshow

Dec 02

NuCana reports Q3 results

Nov 19

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: NCNADie kurzfristigen Aktiva des Unternehmens (£17.3M) übersteigen seine kurzfristigen Passiva (£16.1M).

Langfristige Verbindlichkeiten: NCNADie kurzfristigen Vermögenswerte des Unternehmens (£17.3M) übersteigen seine langfristigen Verbindlichkeiten (£212.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: NCNA ist schuldenfrei.

Schulden abbauen: NCNA hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: NCNA hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: NCNA hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 7% pro Jahr abnimmt

NuCana Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Recent updates

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

New minor risk - Shareholder dilution

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 9.5% to US$4.79

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Insufficient new directors

New major risk - Financial position

New major risk - Revenue and earnings growth

New major risk - Share price stability

Nucana plc Announces Presentation on Ongoing Nutide:701 Study of Nuc-7738 At the Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics 2023

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

NuCana plc Presents Encouraging Data on NUC-3373 in Colorectal Cancer At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana plc, Annual General Meeting, Jun 15, 2023

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Price target increased by 10% to US$4.38

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$3.42

Price target decreased to US$4.26

NuCana plc Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Price target decreased to US$4.26

NuCana: An Intriguing 'Sum Of The Parts' Story

Nucana Presents Promising Data on NUC-7738 At the European Society of Medical Oncology (Esmo) Annual Meeting 2022

NuCana GAAP EPS of -£0.07

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana regains Nasdaq compliance

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Price target decreased to US$4.69

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Less than half of directors are independent

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$9.00

Price target decreased to US$11.67

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

NuCana plc Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

NuCana: Preparing For A Critical 2022

Price target increased to US$17.25

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

New 90-day low: US$4.38

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

New 90-day high: US$6.40

New 90-day low: US$4.40

NuCana plc Appoints Andrew Kay as Chairman of its Board of Directors

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Price target lowered to US$17.29

NuCana (NCNA) Investor Presentation - Slideshow

Nucana plc Announces Final Data from the Phase Ib Study of Acelarin Plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in the Oncologist

Price target raised to US$19.00

NuCana reports Q3 results

New 90-day low: US$4.45

NuCana plc Announces the Appointment of Bali Muralidhar, M.D., Ph.D. to Its Board of Directors

NuCana plc Announces Data from Ongoing NUC-3373, NUC-7738 and Acelarin Phase III Study

New 90-day low: US$4.58

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen